Eureka Genomics Lands a DHS Phase II Award for $750,000

HOUSTON--(EON: Enhanced Online News)--The Department of Homeland Security (DHS) Science and Technology Directorate (S&T) have awarded Eureka Genomics Corporation a $750,000 Phase II SBIR for the detection of rare variants of Bacillus anthracis.

After successfully completing a DHS Phase I contract, Eureka Genomics has been awarded a $750,000 Phase II SBIR from The Department of Homeland Security (DHS) Science and Technology (S&T), to be completed by June 2013. According to Dr. Viacheslav Fofanov, Director of Bioinformatics for Eureka Genomics, "The ability to detect the presence of rare variants (either known or previously uncharacterized) in cell populations (viral, bacterial, and eukaryotic) could lead to significant improvements in the ability to fingerprint a sample and, as a consequence, provide vital information for the investigation and prosecution of bioterrorism attacks or attempts. In addition to forensic applications, the ability to detect rare or minority variants in bacterial and viral populations can significantly contribute to understanding of the complex host-pathogen interaction process and lead to new ways to diagnose and treat infections caused by microorganisms such as HIV, HCV, and Mycobacterium tuberculosis and cancers where there are multiple choice of therapeutics."

The development of novel methods for the detection of microorganisms is part of Eureka Genomics main research and business focus. The Company is currently working on the identification of microorganisms associated with colorectal cancer, in collaboration with Baylor Research Institute, and the identification of microorganisms associated with preterm birth.

About Eureka Genomics: Eureka Genomics is a privately held company and leader in the advanced bioinformatics analysis of next-generation sequencing data, which it applies to the discovery of novel microorganisms associated with cancers and other life threatening diseases. The company further leverages its proprietary algorithms and biological problem-solving expertise by providing collaborative, high quality sequencing and analysis services on a cost-effective basis to a broad range of university, governmental and industry researchers around the world. www.eurekagenomics.com

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.